Release Date: March 11, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you provide more specific guidance on the European filing timelines for MyPIFA and how the European market dynamics might influence your strategy? A: Neil McFarlane, CEO, explained that they plan to file a marketing authorization application in Europe in the second half of 2025. The European market is more mature due to the long-standing presence of Miglustat, which has led to more diagnosed and treated patients. They believe MyPIFA, in combination with Miglustat, can halt disease progression, offering a significant opportunity in Europe. Adrian Quartel, Chief Medical Officer, added that they are consulting with experts to address previous regulatory feedback and are confident about the filing's acceptance.
Q: How conservative is your cash runway guidance, and does it include potential European approval? A: Leanne Clifton, CFO, stated that the cash runway guidance is conservative and does not include proceeds from the priority review voucher sale. The focus is on executing current plans, and the guidance does not account for potential European approval.
Q: Can you provide more details on the sales during the quarter and expectations for net patient additions? A: Leanne Clifton, CFO, mentioned that Q4 revenue included initial patient dispenses and some refills, with stock levels maintained at target levels. Josh Schaffer, Chief Commercial Officer, highlighted the rapid conversion of expanded access program patients and the focus on identifying and treating diagnosed but untreated patients, as well as those not yet diagnosed.
Q: What are the key variables influencing the trajectory of patient enrollment forms for MyPIFA? A: Josh Schaffer, Chief Commercial Officer, noted that many patients were ready to transition from the expanded access program. The focus is now on expanding beyond these sites to reach more diagnosed patients and those at centers of excellence.
Q: How are reimbursement conversations progressing, and what is the expected net revenue per patient? A: Josh Schaffer, Chief Commercial Officer, explained that they are emphasizing MyPIFA's clinical benefits in discussions with payers. Most patients are getting coverage through formulary or medical exceptions. Leanne Clifton, CFO, mentioned that it's too early to discuss gross-to-net details, but they expect a solid position without aggressive pricing strategies.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.